53 results about "Stage tumor" patented technology

The invention discloses a bovine serum albumin combined nano antibody and a preparation method and application thereof, the amino acid sequence of the bovine serum albumin combined nano antibody Nb1 is shown as SEQ.ID No.1, the nano antibody Nb not only has high affinity to bovine serum albumin, but also has good binding activity to both human serum albumin and mouse serum albumin, and the nano antibody Nb has high affinity to human serum albumin and mouse serum albumin. And the antibody has a relatively good broad-spectrum application range, and can be widely applied to the aspects of drug half-life period enhancement, tumor targeted therapy and imaging, immunodetection or diagnosis, recombinant albumin purification or enrichment and the like.

The invention discloses a cat serum albumin combined nano antibody as well as a preparation method and application thereof, and relates to the technical field of nano antibody engineering. Wherein the amino acid sequence of the cat serum albumin binding nano antibody Nb1 is shown as SEQ.ID NO.1, and the nano antibody Nb1 not only has higher affinity to cat serum albumin, but also has better binding activity to mouse serum albumin; the polypeptide can be widely applied to the aspects of drug half-life period enhancement, tumor targeted therapy and imaging, immunodetection or diagnosis, recombinant albumin purification or enrichment and the like in the pet treatment process.

The present invention relates to a nanomaterial for preventing tumor bone metastasis, a preparation method therefor, and use thereof. The present invention has discovered a spatiotemporal coupling interaction between tumor cells and osteoclasts, and provides a tumor-bone initial metastasis behavior-targeting strategy which can accurately prevent tumor metastasis on the basis of the source, and can avoid drug resistance and biochemical drug resistance. On this basis, the present invention designs a physical killing nanomaterial targeting tumor-osteoclast conjugates, the nanomaterial being a bone targeting group-modified nanovesicle encapsulating a carbonate compound and a phosphate compound. The nanomaterial can be effectively concentrated in bone tissue; when tumor cells are activated, the acid secretion function of tumor-related osteoclasts in nearby tumor-osteoclast conjugates which are in contact with the tumor cells triggers the carbonate compound to generate carbon dioxide gas and promotes the release of the phosphate compound, which forms calcium phosphate crystals with calcium ions so as to kill nearby tumor cells, thus achieving a specific very-early tumor metastasis inhibition effect.

The invention discloses a colorectal early-stage tumor data analysis early-warning method based on reinforcement learning, and the method comprises the steps: achieving the semantic alignment and weighted fusion through the unified expression of different modal features, and employing a differentiable attention unit; dynamic strategy optimization is carried out in combination with a reinforcement learning model, and the generalization ability and early warning accuracy of heterogeneous data are improved; a dynamic weight adjustment and online learning mechanism is introduced, continuous self-adaptive updating of the model and compensation of a data missing scene are realized, the accuracy and stability of colorectal tumor risk early warning are improved, and the method has high clinical application and popularization value.

The invention discloses a method for accurately identifying benign and malignant cells based on multi-dimensional characteristics of a single cell transcriptome, and belongs to the technical fields of bioinformatics, tumor molecular biology and cell identification. On the basis of single cell transcriptome sequencing data of tumor tissues and para-carcinoma tissues, three types of information including copy number variation, allele specific copy number variation and tumor-related transcriptional characteristics are synthesized, and final benign and malignant identification is performed on each EpCAM positive epithelial cell through a multi-evidence voting strategy. The method disclosed by the invention has relatively high stability and accuracy in a multi-patient, multi-sample and early tumor scene, particularly improves the recognition capability of early lesion and malignant cells in benign and malignant boundary transition state cells, and provides a reliable technical means for precise diagnosis and individualized treatment of tumors.

This disclosure relates to a method for detecting colorectal cancer. The method comprises determining whether an advanced neoplasm is present in a first screening time period and upon determining that an advanced neoplasm is present in the first screening time period, performing colonoscopy in a second screening time period, after the first screening time period, to detect colorectal cancer. There is further provided a method for stratification of a subject comprising upon detection of an advanced neoplasm in a first screening time period, stratifying the subject into a high risk stratification for developing colorectal cancer in a second screening time period. There is further provided a computer implemented method for calculating a risk score for developing colorectal cancer comprising determining patient data; applying a trained machine learning model to the patient data to determine the risk score; and outputting the risk score.

The application provides a kind of nanoparticle, preparation method and its early screening related application of cancer, wherein, nanoparticle includes superparamagnetic nanometer core, cationic polymer modified on the surface of superparamagnetic nanometer core and targeted polypeptide grafted on cationic polymer, the targeted polypeptide can specifically recognize tumor specific antigen protein, and has the modular structure of rigid helix and charge repulsion sequence.The plasma low-abundance protein enrichment nanoparticle provided by the application can be used for the detection of early screening of tumor through liquid biopsy, can significantly improve the detection rate of early tumor, and has important clinical significance.

The present invention discloses a bovine serum albumin-binding nanoantibody and its preparation method and application. The amino acid sequence of the bovine serum albumin-binding nanoantibody Nb1 is shown in SEQ.ID No.1. The nanoantibody Nb not only has a high affinity for bovine serum albumin, but also has good binding activity to human serum albumin and mouse serum albumin. It has a good broad-spectrum application range and can be widely used in enhancing drug half-life, tumor targeted therapy and imaging, immune detection or diagnosis, recombinant albumin purification or enrichment, etc.

The present invention relates to improved methods for screening, diagnosing and / or monitoring colorectal advanced neoplasia (AN), advanced adenoma (AA) and / or colorectal cancer (CRC), wherein AN includes CRC and AA. In particular, the method provides increased specificity due to a reduction in false positive results in fecal occult blood tests (FOBTs) using characteristics based on bacterial markers. The present invention further relates to the use of the method in selecting subjects for exploratory testing (e.g., colonoscopy) or for treatment with anticancer therapy.

The invention provides a nanoparticle, a preparation method and a cancer early screening related application thereof, the nanoparticle comprises a superparamagnetic nano core, a cationic polymer modified on the surface of the superparamagnetic nano core and a targeting polypeptide grafted on the cationic polymer, the targeting polypeptide can specifically recognize a tumor specific antigen protein, and has a modular structure comprising a rigid helix and a charge repulsion sequence. The plasma low-abundance protein-enriched nanoparticles provided by the invention can be used for early screening detection of tumors through liquid biopsy, can significantly improve the detection rate of early tumors, and have important clinical significance.

The invention relates to the technical field of small-molecule contrast agents, in particular to a small-molecule contrast agent and a preparation method thereof. According to the micromolecule contrast agent provided by the invention, a divalent glycosyl group is introduced into a binary triiodo-benzene ring structure, so that each molecule contains six iodine atoms (the theoretical iodine content reaches 48.7 wt%), the molecular weight is controlled to be 2000Da or below, the water solubility is remarkably improved, the viscosity is reduced, and the performance is superior to that of a traditional contrast agent. Preliminary CT imaging experiments show that under the same molar concentration, the average CT value generated by the contrast agent YJY-86-2 is obviously higher than that generated by iohexol, and the contrast agent shows stronger imaging contrast ability. The characteristic is expected to realize better image quality while reducing the dosage of administration and reducing the risk of iodine exposure, and provides a powerful candidate material for realizing high-sensitivity detection of early tumors.

The present invention provides a method for predicting the treatment effect of superficial early-stage gastric tumor lesions, which relates to the technical field of treatment effect prediction. The method comprises: performing an initial image scan on a patient to be treated to obtain a preoperative image set; performing parameter sequence extraction on the preoperative image set to obtain an initial parameter sequence set; obtaining an initial derived parameter set based on the initial parameter sequence set; performing surgical treatment on the patient to be tested based on the derived parameter set to obtain a patient to be tested; performing a secondary image scan on the patient to be tested to obtain a postoperative image set; performing parameter sequence extraction on the postoperative image set to obtain a secondary parameter sequence set; obtaining a secondary derived parameter set based on the secondary parameter sequence set; obtaining a first ROI map and a second ROI map based on the derived parameter set and the secondary derived parameter set; and inputting the first ROI map and the second ROI map into a treatment effect prediction model to obtain a prediction result. The present invention solves the problem of low accuracy in treatment effect prediction in the prior art.

The invention discloses application of combination of carboxamidotriazole and revatinib in preparation of liver cancer drugs, a pharmaceutical composition and a preparation of the carboxamidotriazole and the revatinib, the drug combination of carboxamidotriazole and revatinib is used for the first time, the carboxamidotriazole and the revatinib show a remarkable synergistic effect, and in clinical medication, for patients with low sensitivity of using revatinib, the drug combination of carboxamidotriazole and revatinib has a remarkable curative effect on liver cancer. Through combination with carboxamidotriazole, the sensitivity of a patient to the medicine can be improved, and a synergistic effect is achieved. Meanwhile, as a non-cytotoxic drug, the carboxamide triazole can regulate the tumor inflammatory microenvironment, so that the tumor growth environment is changed, and the possibility of later development and metastasis of tumors is reduced. Meanwhile, the combination of carboxamidotriazole and lenvatinib has high safety, and provides more medication options for first-line patients.

The invention relates to the technical field of medical treatment, and discloses a transfer learning method for bad outcome prediction of small-sample early-stage cancer patients. According to the method, the neural network risk function is introduced and the transfer learning framework is combined, so that the nonlinear interaction of high-dimensional features can be better fitted, and the prediction accuracy of the small-probability bad outcome of the early-stage tumor is improved. Although the existing RSF can overcome linear hypothesis to a certain extent, the existing RSF is susceptible to noise interference in a small sample queue, and the prediction stability is insufficient. According to the migration survival forest method provided by the invention, by training and migrating structure priori on a large-scale database, a stable tree structure can be kept under a small sample condition, and a split threshold is re-estimated in combination with target data, so that global structure knowledge and local adaptability are taken into consideration, and the reliability of the system is improved. Therefore, the robustness and generalization ability of the model are remarkably improved.

The invention relates to the technical field of gynecological tumors, and discloses a gynecological tumor disease risk intelligent prediction system which comprises a data acquisition module, a data storage module, a data analysis module, a feature extraction module, a model training module, a risk prediction module and a result display and feedback module. According to the intelligent risk prediction system for the gynecological tumor diseases, the data related to the gynecological tumor diseases are rapidly extracted through the data analysis module and the feature extraction module by adopting the clinical symptoms, family medical history, living habits, various examination indexes and other multi-dimensional data of patients, and the data related to the normal range numerical values are compared in a brush year; by means of the method, potential risk signals can be accurately captured when obvious clinical symptoms or signs do not appear in the early stage of the disease, by increasing associated data, the discovery rate of early tumor diseases is increased, precious treatment time is won for patients, and the healing possibility and the prognosis effect are greatly improved.

This invention discloses an RNA-reactive fluorescent probe, its preparation method, and its application in tumor imaging and treatment. Upon response to ALP enzyme, the probe exhibits enhanced fluorescence, with a corresponding increase in photoacoustic intensity at 685 nm. Simultaneously, after enzyme response, the probe reacts with cytoplasmic RNA under red light irradiation, prolonging its residence time in tumor cells and achieving long-window tumor imaging. More importantly, this cross-linking reaction causes mitochondrial damage, leading to severe tumor cell apoptosis and thus inhibiting tumor growth. This invention's probe not only enables long-window near-infrared and photoacoustic dual-modal imaging of tumors but, more importantly, inhibits tumor growth, achieving integrated tumor diagnosis and treatment.

A method and computer-based system is provided that assists physicians in detecting early tumor growth, for example, glioblastoma (GMB) and low-grade gliomas, and allowing modification of treatment to have a positive impact on medical management, patient morbidity, outcomes and survival times. The method comprises measuring tumor volumes from radiological images to predict growth by a statistical method. The methods allow detection of increases in tumor size earlier than is currently possible and, therefore, advantageous in modifying or optimizing treatment.

The invention belongs to the technical field of gene editing, and particularly relates to a construction method of a transgenic mouse with a tissue-specific precancerous marker. A fertilized ovum is constructed through a gene editing technology, a mutant p53 protein and a fluorescent protein are fused, a loxp-Stop-loxp sequence is added in front of a promoter of a mutant p53 sequence, the fertilized ovum is transplanted into a female mouse, the obtained progeny is an LPL transgenic mouse, and expression inhibition of the mutant p53 protein and the fluorescent protein is achieved; the LPL transgenic mouse is mated with a Cre tool mouse to obtain a transgenic mouse of which the offspring is a tissue-specific precancerous marker, the transgenic mouse expresses mutant p53 protein and fluorescent protein at a specific tissue, early tumor focus development is monitored and traced through a living body fluorescence imaging system, and the LPL transgenic mouse has extremely high application and research values.

The invention discloses a digestive tract tumor early screening system based on multi-omics data fusion, and relates to the technical field of tumor screening, the system comprises a double sample collection module, a synchronous detection module, a database support module, a fusion analysis module and a visual output module; according to the method, the accuracy and comprehensiveness of early screening of digestive tract tumors are improved through multi-omics data fusion, multi-dimensional data of fecal microbial genome DNA, metabolites, blood ctDNA and protein markers are integrated, biological information of four levels of florae, metabolism, genes and proteins is covered, and the accuracy and comprehensiveness of early screening of digestive tract tumors are improved through a three-level cross validation mechanism. According to the method, flora-metabolite synergy abnormality and gene-protein synergy abnormality can be recognized, the tumor risk value is calculated and the risk level is set in combination with positive threshold values and clinical weights in a multi-omics feature database, the detection rate of early tumors is increased, and the method has higher sensitivity especially for early digestive tract tumors without obvious symptoms.

This invention discloses a feline serum albumin-bound nanobody, its preparation method, and its applications, relating to the field of nanobody engineering technology. The amino acid sequence of the feline serum albumin-bound nanobody Nb1 is shown in SEQ.ID NO.1. The nanobody Nb1 not only exhibits high affinity for feline serum albumin but also good binding activity to mouse serum albumin, and can be widely applied in enhancing drug half-life during pet treatment, tumor targeted therapy and imaging, immune detection or diagnosis, and recombinant albumin purification or enrichment.

The invention discloses an anti-CD33 nano antibody as well as a preparation method and application thereof, and belongs to the technical field of nano antibodies. The invention provides a nano antibody for resisting a CD33 target spot, and the nano antibody has an antibody-dependent cell-mediated cytotoxic effect. The nano antibody has high affinity with both CD33 full-length protein and CD33 membrane-proximal terminal protein, obviously reduces immune risks caused by heterology, is more beneficial to penetrating a blood-brain barrier, can be used as an antigen binding domain for designing CAR, is easier to reach the interior of a tumor to play a therapeutic effect, and has a wide application prospect in preparation of drugs for preventing and / or treating advanced tumors.

The invention provides a tumor treatment responsiveness evaluation method, equipment and device, and the method comprises the steps: analyzing the influence of each immune cell subset of peripheral blood on tumor treatment response by adopting a single-factor logistic regression model, and obtaining an immune cell subset which plays a significant role in a patient with treatment response compared with a patient without treatment response; and based on the screened immune cell subgroups, establishing a classification prediction model for predicting response and non-response treatment states of a patient receiving tumor treatment. The peripheral blood immune pattern of the patient can be evaluated by detecting the peripheral blood immune cell subgroups of the advanced tumor patient; and furthermore, the benefit probability of the advanced tumor patient receiving the small-dose rhythm chemotherapy is accurately and dynamically predicted, and a relatively high reference value is provided for the selection of a treatment scheme.

The present invention discloses a non-invasive early screening method and system for cancer based on the length distribution characteristics of cfDNA fragments. This method uses a relatively low-depth whole-genome sequencing method to statistically analyze the differences in the fragment length distribution characteristics of tumor-derived cfDNA and healthy individual-derived cfDNA, establish an early screening model for cancer, and achieve non-invasive early screening for cancer. The scheme of the present invention focuses on the characteristic of blood cfDNA fragment size to distinguish ctDNA from non-tumor-derived cfDNA. It does not rely on the mutation detection of oncogenes or tumor suppressor genes, and eliminates the interference caused by clonal hematopoietic mutations. Secondly, the data of the embodiments of the present invention show that the size characteristics of blood cfDNA fragments can be used to distinguish between healthy people and early-stage tumor patients. Finally, due to the use of low-depth whole-genome sequencing technology, the detection costs involved in the scheme of the present invention are greatly reduced, which is conducive to future applications in the field of early screening of malignant tumors.

The invention discloses a quantum sensing method for cross-class combined detection of tumor markers, which utilizes the quantum optical characteristics of an NV color center in a fluorescent nano-diamond as sensing signals to realize cross-class combined detection of two mainstream markers (miRNA and protein) in diagnosis of tumor diseases. The surface of the nano-diamond is functionally modified, and the charge state proportion situation of the NV color center is presented in a spectrum shape, so that the miRNA is detected. By constructing the magnetized gel, the detection of protein markers can be realized by utilizing an optical detection magnetic resonance (ODMR) signal of an NV color center. According to the method, on the basis that NV color center quantum has multiple optical signal characteristics, sensitive detection of miRNA-155 and MUC1 proteins is realized. The two sensing signals of the method are unisource and heterogeneous, so that the two sensing signals do not interfere with each other, and the method is suitable for sensitive and accurate detection of early tumor disease markers.

This invention belongs to the field of biodetection and medical technology, and relates to a high-performance photothermal diagnostic and therapeutic integrated fiber optic probe based on rare-earth nanomaterials. The probe includes a photothermal diagnostic and therapeutic composite material. This material consists of a tumor-specific environmental fluorescence responsive material, 1,8-naphthalimide fluorophore, and Yb that can be used for photothermal therapy. 3+ / Er 3+ The probe is composed of co-doped Bi₂WO₆ nanomaterials. Under 450nm laser excitation, the fluorescently responsive material in the probe emits 550nm green fluorescence in a tumor cell environment, which is received and fed back by the fiber optic probe, enabling specific recognition of tumor cells. After recognition, the fiber optic probe emits fluorescence that can be detected by Yb 3+ / Er 3+ The co-doped Bi₂WO₆ nanomaterials absorb and convert infrared light in the 980nm near-infrared band into photothermal radiation. Under continuous irradiation, the nanomaterials continuously heat up, destroying cell structures and killing tumor cells, thus achieving targeted photothermal monitoring and treatment of tumor cells. This probe is minimally invasive and has high photothermal conversion efficiency, providing a new approach for minimally invasive diagnosis and treatment of early-stage tumors.

PI3Kδ implicates hematologic cancers and solid tumors. Alternative splicing is a post-transcriptional process for acquiring proteomic diversity in eukaryotic cells. Emerging evidence highlights the involvement of aberrant mRNA splicing in cancer development / progression. PI3Kδ-L and PI3Kδ-S are overexpressed in advanced solid tumors, such as prostate, breast, colon, lung and pancreatic cancers. Differential PI3Kδ and PI3Kδ-S expression profiles were identified in a panel of solid tumor cells. PI3Kδ inhibitor Idelalisib and SRPK1 / 2 inhibitor SRPIN340 were employed to assess their efficacies on inhibiting the PI3Kδ-expressing solid tumors. Idelalisib effectively inhibits PI3Kδ-L and its downstream signaling. Idelalisib fails to inhibit PI3Kδ-S activity and its downstream signaling. SRPIN340 reverses the aberrant mRNA splicing, thereby inhibiting the downstream AKT / mTOR signaling. In vitro functional assays further demonstrate that a combination of Idelalisib and SRPIN340 achieve a synergistic drug effect, with drastically reduced cell viabilities / growths of tumor spheroids, in inhibiting the advanced tumor cells.

The application relates to the fields of biotechnology and targeted therapy, and particularly relates to a recombinant construct, a CAR-T cell and construction and application thereof. The application verifies the role and mechanism of THEMIS in maintaining the long-term killing of tumor cells of CAR-T through experiments. The CAR-T cell overexpressing THEMIS is constructed, compared with a control group, the proliferation capacity and memory cell formation capacity of the THEMIS-7x19 CAR-T cell are enhanced after antigen stimulation, and the cytokines are in a controllable state, the cell apoptosis and exhaustion are reduced, and the long-term tumor killing capacity can be maintained more effectively. The in-vivo experiment also proves that the THEMIS-7x19 CAR-T cell has stronger anti-tumor effect compared with the control group in a lymphoma tumor-bearing mouse model, and the survival time of the mouse is significantly prolonged.

The present invention discloses a chicken - derived recombinant full - length monoclonal IgY antibody against human thymidine kinase 1 (TK1) (hTK1 - IgY - rmAb) and its application. By an improved phage display method, using the C - terminal 195 - 225 polypeptide of human TK1, a chicken - derived recombinant full - length monoclonal IgY antibody against human TK1 was developed. A super - large library of 3.4×10<supgt;9< / supgt> pfu / mL was rapidly constructed within three weeks, and the positive clone rate was as high as 98%. By using ELISA, immunoblotting and immunohistochemical detection methods, an optimized hTK1 - IgY - rmAb antibody with high specificity and high sensitivity was identified. The present invention improves the stability between batches of the antibody, enables the operation of a new generation of TK1 detection kits based on recombinant IgY antibodies on an automated chemiluminescence analyzer, and can meet the detection requirements for large - scale early - stage tumor risk screening.

An independent wearable biomedical imaging system for early tumor detection the system including a physician headset having a graphical display in wireless communication with a patient headset having a left and right camera. The physician headset includes a map template database disposed in the memory storage drive including data specifying anatomical location of a patient tumor using sclera scans of a patient sclera and iris received from the patient headset. The physician can visually access the sclera scans from the patient headset camera and overlay with the map template to compare patient scan biomarkers with the map data. The physician may use the results in indicating strong genotype predisposition to tumors and tumor formation. The system algorithm would continue to amass biodata in the datasets helping the physician to increase accuracy in generating eye reports and statistical probability of tumor as well as genetic marker predisposition of the same.

A method to develop one or more morphometric classifiers to identify a mismatch repair deficiency (MMRD). The method provides a non-invasive method of characterizing MMRD that is responsive to a tumor in its early stages of development and irrespective of the tumor size. The method allows targeting cancer therapy to the specific characteristics of the cancer that the patient may have, allowing more efficient cancer management with far fewer side effects.